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Background: Pertuzumab, trastuzumab, and docetaxel is standard of care for first-line treatment of HER2-positive
metastatic breast cancer (MBC). However, alternative chemotherapy partners are required to align with patient/
physician preferences and to increase treatment flexibility. We report VELVET Cohort 1 results in which the efficacy
and safety of pertuzumab and trastuzumab, administered sequentially in separate infusions, followed by vinorelbine,
were evaluated. Cohort 2, where pertuzumab and trastuzumab were administered in a single infusion, followed by
vinorelbine, recruited after Cohort 1 was fully enrolled, will be reported later.
Methods: In this multicenter, two-cohort, open-label, phase II study, patients with HER2-positive locally advanced or
MBC who had not received chemotherapy or biological therapy for their advanced disease received 3-weekly
pertuzumab (840 mg loading, 420 mg maintenance doses) and trastuzumab (8 mg/kg loading, 6 mg/kg maintenance
doses), followed by vinorelbine (25 mg/m2 initial dose, 30–35 mg/m2 maintenance doses) on days 1 and 8 or 2 and 9
of each 3-weekly cycle. Study treatment was given until investigator-assessed disease progression or unacceptable
toxicity. The primary endpoint was investigator-assessed objective response rate (ORR) in patients with measurable
disease at baseline per RECIST v1.1. Secondary endpoints included progression-free survival (PFS) and safety.
Results: Cohort 1 enrolled 106 patients. Investigator-assessed ORR was 74.2% (95% CI 63.8–82.9) in intent-to-treat
patients with measurable disease (89/106 [84.0%]). Median PFS was 14.3 months (95% CI 11.2–17.5) in the
intent-to-treat population. Treatment was reasonably well tolerated, with no unexpected toxicities. Diarrhea
(61/106 patients [57.5%]) and neutropenia (54/106 [50.9%]) were the most common adverse events (AEs);
neutropenia (33/106 [31.1%]) and leukopenia (14/106 [13.2%]) were the most common grade ≥3 AEs. Serious
AEs were reported in 32/106 (30.2%) patients. AEs led to study drug discontinuation in 36/106 patients
(34.0%). Eighteen of 106 patients (17.0%) had AEs suggestive of congestive heart failure; however, there were no
confirmed cases.
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Conclusions: The vinorelbine, pertuzumab, and trastuzumab combination is active and reasonably well tolerated.
This regimen offers an alternative for patients who cannot receive docetaxel for first-line treatment of HER2-positive
locally advanced or MBC.
Trial registration: ClinicalTrials.gov: NCT01565083, registered on 26 March 2012.
Keywords: Vinorelbine, Trastuzumab, Pertuzumab, Locally advanced breast cancer, Metastatic breast cancerBackground
HER2 overexpression/amplification occurs in 15–20% of
breast cancers [1] and is associated with poor prognosis [2].
Trastuzumab and pertuzumab are humanized monoclonal
antibodies that bind HER2 subdomains IV and II,
respectively [3, 4]. Treatment with both agents offers more
comprehensive signaling blockade than either agent alone,
due to distinct but complementary modes of action [5, 6].
In the pivotal CLEOPATRA trial, first-line treatment
with pertuzumab in combination with trastuzumab and
docetaxel significantly increased independently assessed
progression-free survival (PFS) by 6.1 months (hazard
ratio 0.62, P < 0.001) [7] and overall survival (OS) by
15.7 months (hazard ratio 0.68, P < 0.001) [8], compared
with trastuzumab and docetaxel in patients with
HER2-positive metastatic breast cancer. Docetaxel is an
established and effective cytotoxic agent but for some
selected cases physicians and patients may prefer a
different chemotherapy partner due to prior docetaxel
treatment, or because of its toxicity profile, which may
make it unsuitable for some patients [9, 10]. Therefore, to
increase flexibility in treatment decision-making, there is a
need to investigate other chemotherapies as alternative
partners for pertuzumab and trastuzumab.
The vinca alkaloid vinorelbine demonstrates synergistic
activity with trastuzumab against HER2-overexpressing
breast cancer cells [11]. Multiple trials have shown that
first-line treatment with vinorelbine plus trastuzumab for
HER2-positive metastatic breast cancer is efficacious and
well tolerated [12–22]. Furthermore, the HERNATA study
demonstrated that docetaxel and trastuzumab were not
superior to vinorelbine and trastuzumab in terms of
efficacy in patients with HER2-positive advanced breastPatients with HER2-positive 
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previously treated with systemic 
non-hormonal anti-cancer








and trastuzumab in 
(from cycle 2 on
by vino
Fig. 1 Study design. a Sample size was based on assuming a best overall r
after Cohort 1 had finished enrolling patientscancer, but patients who received vinorelbine experienced
fewer grade 3 and 4 adverse events (AEs) than those
treated with docetaxel [22]. Vinorelbine may offer an
alternative to docetaxel but has not yet been tested in
combination with dual HER2-targeted therapy.
The VELVET study is evaluating the efficacy and safety
of pertuzumab, trastuzumab, and vinorelbine for the
first-line treatment of HER2-positive locally advanced or
metastatic breast cancer. Trastuzumab and pertuzumab
were administered either as separate intravenous infusions
(Cohort 1) or co-administered in a single infusion bag
(Cohort 2), followed by vinorelbine. The two-cohort
design was chosen so that in addition to evaluating the
efficacy of vinorelbine as a chemotherapy partner for
pertuzumab and trastuzumab, the feasibility of their
co-administration, which has the potential to increase
convenience and minimize clinic time for patients, could
also be assessed for the first time. Here we report the final
results for Cohort 1.
Methods
Study design
VELVET is a two-cohort, open-label, multicenter phase
II, proof-of-concept trial involving patients with
HER2-positive locally advanced or metastatic breast cancer
who had not received chemotherapy or biological therapy
for advanced disease. Patients in Cohort 1 received
pertuzumab (PERJETA®; F. Hoffmann-La Roche Ltd., Basel,
Switzerland), trastuzumab (Herceptin®; F. Hoffmann-La
Roche Ltd.), and vinorelbine (Bendarelbin; Bendalis GmbH,
Oberhaching, Germany) as separate infusion bags; patients
in Cohort 2 received pertuzumab and trastuzumab as a
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and will be reported elsewhere. Safety reviews were
performed by an independent data monitoring committee
(IDMC) in May 2012 after the first patient was enrolled into
Cohort 1, in January 2013 when all patients had been
enrolled into Cohort 1, and in April 2013 when 102 patients
had received at least two cycles of study treatment. After
this, recruitment into Cohort 2 began and the IDMC
performed reviews of accumulating safety and efficacy data
every 6 months. The final review was in March 2015.
Patients
Eligible patients were ≥18 years, had HER2-positive locally
advanced (not amenable to curative resection) or metastatic
breast cancer as assessed by local laboratory on primary or
metastatic tumor by immunohistochemistry (with 3+
indicating positivity) or in situ hybridization (with a HER2/
chromosome 17 ratio of ≥2.0 indicating positivity), and
measurable and/or non-measurable disease, evaluable
according to Response Evaluation Criteria In Solid Tumors
(RECIST) version 1.1 [23]. HER2 positivity was subsequently
analyzed centrally (Targos Molecular Pathology GmbH,
Kassel, Germany) but central results were not required
prior to enrollment. Additional inclusion criteria were
Eastern Cooperative Oncology Group (ECOG) performance
status 0 or 1, left ventricular ejection fraction (LVEF) of
≥55% at baseline, and a life expectancy of ≥12 weeks.
Patients may have received ≤2 lines of hormonal therapy for
metastatic or locally recurrent disease, one of which could
have been in combination with everolimus.
Exclusion criteria included prior systemic non-hormonal
therapy in the metastatic or locally advanced setting, prior
treatment with anti-HER2 agents, except with neoadjuvant
or adjuvant trastuzumab and/or lapatinib, disease progression
while receiving neoadjuvant or adjuvant trastuzumab and/
or lapatinib, a disease-free interval of <6 months from
completion of neoadjuvant or adjuvant non-hormonal
therapy to time of disease recurrence, uncontrolled central
nervous system metastases, uncontrolled hypertension,
and clinically significant cardiovascular disease.
Procedures
Patients received a pertuzumab loading dose of 840 mg on
day 1 of cycle 1, followed by 420 mg on day 1 of subsequent
3-weekly cycles. Trastuzumab was administered at a loading
dose of 8 mg/kg on day 2 of cycle 1, followed by 6 mg/kg
on day 1 or 2 of subsequent 3-weekly cycles. Vinorelbine
was administered at an initial dose of 25 mg/m2 on days 2
and 9 of cycle 1, followed by 30–35 mg/m2 on days 1 and
8 or days 2 and 9 of subsequent 3-weekly cycles. All
were administered intravenously and were given until
investigator-assessed disease progression or unacceptable
toxicity. In an effort to appropriately monitor safety
during the initial infusion (cycle 1), pertuzumab had to beadministered on day 1 and trastuzumab followed by
vinorelbine on day 2. Vinorelbine was administered in line
with product labeling. The dosing schedule for vinorelbine
was the same as that used in HERNATA [22], with the
exception of cycle 1, in which vinorelbine was administered
at a lower dose to evaluate its tolerability with the addition
of pertuzumab to the treatment regimen. For vinorelbine,
in the case of grade 3 to 4 toxicities, treatment was delayed
until toxicity improved to grade 1, and then the dose was
reduced to 80%. In the case of elevation of bilirubin more
than two times the upper limit of normal or transaminases
more than three times the upper limit of normal the dose
was reduced to 50% [22]. If vinorelbine was discontinued
due to toxicity, antibody therapy was continued until disease
progression; if antibody therapy was discontinued due
to toxicity, vinorelbine was continued until disease
progression. Dose reductions were not permitted for
antibody therapy.
Routine RECIST v1.1-based tumor assessments were
performed at baseline, every three cycles up to 36 months,
and then every six cycles until disease progression. LVEF
assessments were performed at baseline and every three
cycles, by echocardiogram or multi-gated acquisition scan.
ECOG performance status was assessed at baseline, every
three cycles, and 28 days after treatment discontinuation.
Laboratory tests were performed at baseline, every cycle,
and 28 days after treatment discontinuation. AEs and
serious AEs (SAEs) were monitored continuously during
treatment and until 28 days after treatment discontinuation,
and graded according to Medical Dictionary for Regulatory
Activities (MedDRA) version 18.0. Patients with SAEs that
were ongoing at treatment discontinuation were followed
until resolution of the event. Computed tomography or
magnetic resonance imaging brain scans were carried out
during screening only if brain metastases were clinically
suspected and during the study if clinically indicated.Outcomes
The primary endpoint was investigator-assessed objective
response rate (ORR) in patients with measurable disease
at baseline, according to RECIST v1.1 and was based on
the best overall response (BOR, the best response
recorded from the start of trial treatment until disease
progression/recurrence or death). Secondary endpoints
included time to response, duration of response (DoR) in
responders (patients with a confirmed BOR of either
complete response or partial response, confirmed by two
consecutive assessments), PFS, time to progression (TTP),
OS, safety and tolerability, and health-related quality of life
(HRQoL). HRQoL will be reported separately. Safety
analyses included incidence and severity of AEs and SAEs,
incidence of congestive heart failure (CHF), changes in
LVEF during the study, and laboratory test abnormalities.
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Assuming a BOR rate of 70–80% per cohort, and aiming at
a distance from the estimated proportion to the confidence
interval (CI) limits of 8–11%, 95 patients were needed per
cohort. Assuming a withdrawal rate of approximately 10%,
it was planned to enroll 105 patients in each cohort
(calculated using SAS software, version 9.2 and nQuery,
version 6). The BOR rate of 70–80% was chosen based on
published data [7]. All analyses presented are descriptive.
Efficacy analyses were performed in the intent-to-treat
(ITT) population (all enrolled patients). The primary
endpoint, ORR, was summarized by the number and
percentage of responders, together with two-sided 95%
Clopper-Pearson CIs in ITT patients with measurable
disease at baseline. The Kaplan–Meier approach was used
to estimate median time to response, DoR, PFS, TTP,
and OS. Predefined exploratory subgroup analyses were
performed for ORR and PFS, stratified by prior trastuzumab
treatment and by hormone receptor status. Sensitivity
analyses were performed, excluding tumor assessments
performed after the intake of new anticancer therapy
(ORR, PFS, and TTP), and including progressive disease
due to symptomatic deterioration (PFS and TTP). The
median time on study and 95% CIs were estimated using
the reverse Kaplan–Meier method. AEs were evaluated
descriptively in the safety population (all patients who
received at least one dose of any study treatment). The
study end for each cohort is when all patients have been
followed up for at least 2 years after the last patient
was enrolled, within each respective cohort, unless
they have been lost to follow-up, withdrawn consent,
or died. This study is registered with ClinicalTrials.gov,
number NCT01565083. A pertuzumab extension study
(NCT02320435) opened in February 2015 to provide
patients with continued access to pertuzumab.Fig. 2 Trial profile. a In cycle 1, 106 patients received pertuzumab, 104 pati
15 patients ongoing with any study treatment at time of study closure areResults
Patients
From April 2012 to December 2012, 106 patients were
enrolled into Cohort 1 at 44 centers in Europe and the USA
and all were included in the ITT and safety populations. At
data cutoff and study end for Cohort 1 (May 12, 2015), all
patients had discontinued one or more study treatments;
91/106 (85.8%) patients had discontinued all three, and
the remaining 15 (14.2%) patients had ongoing study
treatment (Fig. 2). Progressive disease was the main
reason for discontinuation. Baseline patient demographics
and clinical characteristics are shown in Table 1. Almost
two-thirds of patients (61.3%) had received prior systemic
cancer therapy: 44/106 (41.5%) had received trastuzumab,
40/106 (37.7%) taxanes, and 41/106 (38.7%) anthracyclines.
Seventy of 106 (66.0%) patients had estrogen and/or
progesterone receptor-positive disease. Eighty-eight of 106
(83.0%) patients had their locally tested HER2-positive
disease confirmed by the central laboratory.
Treatment exposure
Median time on study was 27.8 months (95% CI
27.2–28.6). Patients received a median of 15 pertuzumab
cycles (range 1–47), 15 trastuzumab cycles (range 0–47),
and 9.5 vinorelbine cycles (range 0–40). Two patients
received only pertuzumab at cycle 1. The median vinorelbine
dose intensity during the first six cycles was 17.95 mg/m2
per week (range 7.6–22.5).
Efficacy
Investigator-assessed ORR in the 89/106 (84.0%) patients
with measurable disease at baseline was 74.2% (95% CI
63.8–82.9, 66/89 patients); 12/89 (13.5%) patients achieved
a complete response and 54/89 (60.7%) a partial response.
The BOR for all patients is listed in Table 2. The medianents received trastuzumab, and 103 patients received vinorelbine. b The
also counted under administrative/other reasons
Table 1 Baseline characteristics, intent-to-treat population
Characteristic Cohort 1: pertuzumab,
trastuzumab, and
vinorelbine N = 106
Median age, years (range) 56 (30–82)
Female gender 106 (100%)
Geographical region
Europe 91 (85.8%)




Disease type at screening
Visceral 78 (73.6%)
Non-visceral 28 (26.4%)





Disease stage at advanced
breast cancer diagnosis









HER2 status, local assessment
Immunohistochemistry
0 or 1+ 0
2+ 14 (13.2%)
3+ 85 (80.2%)




Not performed 80 (75.5%)
HER2 status, central assessment
HER2-positive 88 (83.0%)
HER2-negative 12 (11.3%)
Not done 2 (1.9%)
Missing 4 (3.8%)
Table 1 Baseline characteristics, intent-to-treat population
(Continued)
Immunohistochemistry
0 or 1+ 8 (7.5%)
2+ 17 (16.0%)
3+ 75 (70.8%)





Not performed 3 (2.8%)
Not evaluable 11 (10.4%)
Missing 4 (3.8%)





Data are number (%).
aPaclitaxel, docetaxel, nab-paclitaxel, or taxane (not otherwise specified)
bEpirubicin, doxorubicin, mitoxantrone, or anthracycline (not
otherwise specified)
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89 patients with measurable disease at baseline. Among
responders (66/106 patients) the median DoR was
13.3 months (range 2.1–29.5; Fig. 3). At data cutoff,
74/106 (69.8%) patients had progressed or died and the
median PFS was 14.3 months (95% CI 11.2–17.5, Table 2
and Fig. 4a). The median TTP was 14.9 months (95% CI
11.3–17.9). The median OS had not been reached by the
end of the study (Fig. 4b), at which time 83/106 (78.3%)
patients were still alive.
Exploratory and sensitivity analyses
Predefined exploratory subgroup analyses for ORR and
PFS stratified by prior trastuzumab treatment and by
hormone receptor status are shown in Table 2.
A sensitivity analysis excluding patients with tumor
assessments performed after the intake of new anticancer
therapy broadly supported the primary analysis for
ORR, median PFS, and median TTP (Table 3). A second
sensitivity analysis, including progressive disease due to
symptomatic deterioration, was also consistent with the
primary PFS and TTP analyses (Table 3).
Safety
Overall, study treatment was reasonably well tolerated, with
no unexpected toxicities. Table 4 lists AEs of any grade with
an incidence of ≥20%; almost all patients experienced an
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Fig. 3 Investigator-assessed duration of response in responders, intent-to-treat population (Cohort 1). The tick marks indicate censoring events
Fig. 4 Progression-free survival (a) and overall survival (b), intent-to-treat population (Cohort 1). Median overall survival was not reached. The tick
marks indicate censoring events
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Table 3 Sensitivity analyses of best overall response, progression-free survival, and time to progression, intent-to-treat population
Cohort 1: pertuzumab, trastuzumab, and vinorelbine
Sensitivity analyses
Excluding tumor assessments after intake
of any new anticancer therapy N = 106
Including progressive disease due to
symptomatic deterioration N = 106
Best overall response NDa
Patients with measurable disease at baseline 89 (84.0%)
Overall response rate 57 (64.0%) [53.2–73.9]
Complete response 10 (11.2%) [5.5–19.7]
Partial response 47 (52.8%) [41.9–63.5]
Stable disease 17 (19.1%) [11.5–28.8]
Progressive disease 5 (5.6%) [1.8–12.6]
Not evaluable 10 (11.2%) [5.5–19.7]
Progression-free survival
Median 12.5 months [10.4–16.8] 13.8 months [11.0–17.3]
Number of patients with events 65 (61.3%) 74 (69.8%)
Number of patients censored 41 (38.7%) 32 (30.2%)
Time to progression
Median 12.9 months [10.5–16.8] 14.3 months [11.2–17.5]
Number of patients with events 62 (58.5%) 72 (67.9%)
Number of patients censored 44 (41.5%) 34 (32.1%)
Data are reported number (%) [95% CI] for best overall response and median number of months [95% CI] or number (%) for progression-free survival and time to
progression. Best overall response was assessed only in patients of the intent-to-treat population with measurable disease at baseline. Progression-free survival
and time to progression were assessed in the intent-to-treat population
aA sensitivity analysis including progressive disease due to symptomatic deterioration was not performed for best overall response
Table 4 Adverse events (any grade) with an incidence of ≥20%,
safety population
Adverse event Cohort 1: pertuzumab,
trastuzumab, and
vinorelbine N = 106














Decreased appetite 23 (21.7%)
Weight decreased 22 (20.8%)
Data are reported number (%)
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most common AEs. Grade 3 or higher AEs (Table 5) were
reported in 64/106 (60.4%) patients; neutropenia (33/106
patients, 31.1%) and leukopenia (14/106 patients, 13.2%)
occurred most frequently. Granulocyte colony-stimulating
factors (G-CSFs) were administered concomitantly in 28/106
(26.4%) patients for the management of neutropenia.
Thirty-two of 106 (30.2%) patients experienced at least one
SAE (Table 5), with febrile neutropenia and hypersensitivity
being the only SAEs experienced by more than two
patients. Investigator-assessed pertuzumab-related AEs
occurred in 70/106 (66.0%) patients, trastuzumab-related
AEs in 79/106 (74.5%) patients, and vinorelbine-related
AEs in 96/106 (90.6%) patients. AEs led to study
drug interruption in 77/106 (72.6%) patients and
discontinuation in 36/106 (34.0%) patients: discontinuation
of pertuzumab, trastuzumab, and vinorelbine in 18/106
(17.0%), 16/106 (15.1%), and 33/106 (31.1%) patients,
respectively. Neutropenia led to vinorelbine discontinuation
in 4/106 (3.8%) patients; no patients discontinued
treatment due to febrile neutropenia, leukopenia, or
diarrhea. Of the 23 deaths that occurred in the safety
population, 18/23 (78.3%) were from disease progression
and there was one case each of myocardial infarction
(4.3%), septic shock (4.3%), and pneumonia (4.3%). For the
Table 5 Adverse events of grade ≥3 with an incidence of ≥3%
and serious adverse events in >1 patient, safety population
Adverse event Cohort 1: pertuzumab, trastuzumab,
and vinorelbine N = 106
Any grade ≥3 adverse event 64 (60.4%)
Neutropenia 33 (31.1%)
Leukopenia 14 (13 · 2%)
Diarrhea 7 (6.6%)
Anemia 6 (5.7%)




Total number of serious adverse
events
44
Number of patients with ≥1
serious adverse event
32 (30.2%)
Febrile neutropenia 6 (5.7%)
Hypersensitivity 5 (4.7%)
Abdominal pain 2 (1.9%)
Drug hypersensitivity 2 (1.9%)
Pneumonia 2 (1.9%)
Pyrexia 2 (1.9%)
Septic shock 2 (1.9%)a
Adverse events leading to death
(grade 5)
2 (1.9%)a–c
Data reported are n (%)
aOne patient died from septic shock while on treatment
bOne patient died of a myocardial infarction while on treatment
cA further 21 deaths were recorded at the end of the study but they did not
occur while patients were on study treatment; one death due to pneumonia,
two deaths due to unknown causes, and 18 deaths due to disease progression
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unknown.
Cardiac disorders occurred in 16/106 (15.1%) patients.
In three patients these were grade ≥3: grade 3 left
ventricular dysfunction in one (0.9%) patient, grade 3
supraventricular tachycardia in one (0.9%) patient and
grade 5 myocardial infarction in one (0.9%) patient.
Eighteen of 106 (17.0%) patients had AEs suggestive of
CHF: nine (8.5%) patients had LVEF declines (of which
four [3.8%] had declines to <45%), two (1.9%) patients
had left ventricular dysfunction, six (5.7%) patients had
peripheral edema, one (0.9%) patient had orthopnea,
and three (2.8%) patients had peripheral swelling (one
patient had three events [LVEF decline, peripheral
edema, and orthopnea] and one patient had two events
[LVEF decline and peripheral edema]). However, there
were no confirmed cases of CHF. Aside from the nine
patients above, a further two (1.9%) experienced LVEF
declines to <45%; all but two patients’ LVEF recovered
to ≥50%.Anticancer therapies after discontinuation of study
treatment
Ninety of 106 (84.9%) patients received anticancer
therapies after discontinuing study treatment (Table 6).
Of these 90 patients, 57 (63.3%) received trastuzumab, 30
(33.3%) capecitabine, 27 (30.0%) lapatinib, 24 (26.7%)
taxanes, and 17 (18.9%) trastuzumab emtansine.
Discussion
The combination of pertuzumab, trastuzumab, and
docetaxel is standard of care for first-line treatment of
HER2-positive metastatic breast cancer [24]. Although
docetaxel is an active and well-established chemotherapy it
may not always be patients’ or physicians’ preference due to
its toxicity profile or due to prior docetaxel treatment.
Therefore, alternative chemotherapy partners, such as
vinorelbine, are needed to increase options and convenience.
VELVET is the first clinical trial to assess a
non-taxane-based chemotherapy in combination with
pertuzumab and trastuzumab for the first-line treatment
of HER2-positive locally advanced or metastatic breast
cancer. As VELVET was a single-arm proof-of-concept
study, ORR, defined by RECIST guidelines, was
considered to be an appropriate endpoint to directly
measure the study treatment effect in a timely manner.
Here we report the results from Cohort 1 only, where the
study drugs were given sequentially as separate infusions
as per current clinical practice.
The combination of pertuzumab, trastuzumab, and
vinorelbine resulted in an investigator-assessed ORR of
74.2% (95% CI 63.8–82.9, 13.5% complete response and
60.7% partial response) and a median time to response of
2.1 months (range 0.0–29.0) in patients with measurable
disease at baseline. The median PFS was 14.3 months
(95% CI 11.2–17.5), the median TTP was 14.9 months
(95% CI 11.3–17.9), and the median DoR in responders
was 13.3 months (range 2.1–29.5).
The results of VELVET Cohort 1 show that the
combination of vinorelbine plus trastuzumab and
pertuzumab is active in the first-line setting and that
the addition of pertuzumab does not markedly change
the toxicity profile of vinorelbine plus trastuzumab.
Efficacy appeared not to differ greatly versus the
results of a prior study with first-line trastuzumab and
vinorelbine (HERNATA), which demonstrated that this
combination was an active and well-tolerated alternative
to trastuzumab and docetaxel for first-line treatment of
HER2-positive locally advanced or metastatic breast
cancer [22]. However, as VELVET had no control arm, it
is not possible to know what the activity of vinorelbine
and trastuzumab without pertuzumab would be in the
VELVET population.
The efficacy reported in VELVET also appears lower
than that observed in CLEOPATRA where docetaxel was
Table 6 Anticancer treatments received by patients after
discontinuing study treatment, safety population
INN class/preferred terma Cohort 1: pertuzumab,
trastuzumab, and
vinorelbine
N = 106b n = 90c
HER2-targeted treatmentd,e (also counted in individual classes)





Trastuzumab emtansine 17 (18.9%)
Alkylating agents
Patients who received any treatment 6 (6.7%)
Cyclophosphamide 6 (6.7%)
Antiestrogens









Patients who received any treatment 19 (21.1%)
Eribulin 3 (3.3%)
Temsirolimus 1 (1.1%)
Trastuzumab emtansine 17 (18.9%)
Aromatase inhibitors










Patients who received any treatment 2 (2.2%)
Leuprorelin 2 (2.2%)
Table 6 Anticancer treatments received by patients after
discontinuing study treatment, safety population (Continued)
Monoclonal antibodies





Patients who received any treatment 1 (1.1%)
Dicloxacillin 1 (1.1%)
Platinum compounds
Patients who received any treatment 5 (5.6%)
Carboplatin 3 (3.3%)
Cisplatin 2 (2.2%)
Surgical and medical procedures
Patients who received any treatment 22 (24.4%)
Brain tumor operation 1 (1.1%)
Breast operation 1 (1.1%)
Gamma radiation therapy to brain 1 (1.1%)
Lesion excision 1 (1.1%)
Lymphadenectomy 1 (1.1%)
Malignant tumor excision 2 (2.2%)
Mastectomy 5 (5.6%)
Radiotherapy 8 (8.9%)
Radiotherapy to brain 5 (5.6%)
Radiotherapy to lung 1 (1.1%)
Radiotherapy to lymph nodes 1 (1.1%)
Taxanes




Patients who received any treatment 1 (1.1%)
Etoposide 1 (1.1%)
Tyrosine kinase inhibitors




Patients who received any treatment 11 (12.2%)
Vinorelbineg 11 (12.2%)
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Table 6 Anticancer treatments received by patients after
discontinuing study treatment, safety population (Continued)
Combinationsd (also counted in individual classes)








Data reported are number (%).
aINN classes are presented alphabetically and preferred terms are sorted
within INN classes alphabetically
bNumber of patients in the safety population
cNumber of patients who received at least one anticancer treatment after
discontinuing study treatment. Percentages are based on n. Patients may have
received more than one anticancer treatment after discontinuing study
treatment. Some therapies began before the last study treatment was received
dAll preferred terms within the “HER2-targeted treatment” and “Combinations”
summaries are also included in their respective INN classes
eThe “HER2-targeted treatment” summary is a reclassification of specific
preferred terms, identified by the medical team
fThe “Antineoplastic agents” summary includes any drug used to treat cancers
that cannot be assigned to a more specific pharmacological class
gEleven patients had vinorelbine (re)introduced after study treatment was
discontinued: six patients who had stopped study treatment due to an
adverse event/unacceptable toxicity (three of whom had not received on
study vinorelbine due to AE with pertuzumab and/or trastuzumab
administration and had discontinued study treatment before receiving
vinorelbine as an anticancer therapy); three patients who had stopped study
treatment due to administrative/other reasons; and two patients who had
stopped study treatment due to disease progression
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trastuzumab; while ORR was broadly similar, median PFS
and DoR looked shorter when vinorelbine was combined
with the two monoclonal antibodies rather than docetaxel
[7, 8]. However, caution must be exercised when doing
cross-trial comparisons, given the significantly different
study designs (randomized phase III versus single-arm
phase II) and primary endpoints (PFS in CLEOPATRA
and TTP in HERNATA versus ORR in VELVET), different
patient populations (VELVET had no Asian patients, and
had a higher number of hormone receptor-positive
patients and a higher frequency of patients with visceral
disease at baseline than CLEOPATRA), and the different
number and type of prior anticancer therapies [22].
Importantly, a high percentage of patients in VELVET
Cohort 1 (41.5%) received prior neoadjuvant or adjuvant
trastuzumab, which makes VELVET more representative of
current real-world patient populations than earlier trials.
However, unexpectedly, based on current understanding of
the potential mechanisms of resistance to HER2-directed
therapies [25], the ORR in VELVET Cohort 1 was slightly
higher in patients who had prior trastuzumab treatment
than in trastuzumab-naïve patients. Overall, given the
exploratory nature of this subgroup analysis, the small
numbers of patients, and wide overlapping CIs, this finding
should be interpreted with caution.Sensitivity analyses (excluding tumor assessments
performed after the intake of new anticancer therapy,
and including progressive disease due to symptomatic
deterioration) to test the robustness of ORR, PFS, and
TTP were broadly consistent with the primary efficacy
analyses. Two-year survival was 78.3% at clinical cutoff.
Median OS, a secondary endpoint, had not been reached,
suggesting 2 years is too short for OS follow-up.
The treatment regimen was reasonably well tolerated with
no unexpected toxicities, and consistent with the known
safety profiles of the individual agents, and with the
favorable toxicity observed in clinical trials combining
trastuzumab and vinorelbine versus other chemotherapy
options in the HER2-positive metastatic setting [12–22].
Diarrhea and neutropenia were the most common AEs.
The incidence of grade ≥3 diarrhea was low and no
patients discontinued treatment from it. The incidence of
grade ≥3 neutropenia was 31.1%, but this was managed
with G-CSFs and only four (3.8%) patients discontinued
treatment due to neutropenia. While acknowledging
the caveats of cross-trial comparisons, as expected the
incidence of grade ≥3 neutropenia and febrile neutropenia
was lower with pertuzumab, trastuzumab, and vinorelbine
than that reported for pertuzumab, trastuzumab, and
docetaxel in CLEOPATRA (31.1% versus 48.9%, and 5.7%
versus 13.8%, respectively). The incidence of grade ≥3
diarrhea was similar (6.6% versus 7.9%), and the incidence
of grade ≥3 asthenia slightly higher in VELVET Cohort
1 (4.7% versus 2.5%) [7]. The safety findings are not
surprising given the well-documented toxicity profiles
of docetaxel [9] and vinorelbine [26].
The relatively small number of patients and the lack of a
comparator arm may limit the interpretation of this study.
However, a single-arm phase II study such as VELVET
may be sufficient to provide insights on the efficacy and
safety of a novel regimen, particularly as large clinical trial
datasets of the investigational drugs are already available
in similar therapeutic settings.
Beyond VELVET, one small phase II study has
investigated paclitaxel as an alternative to docetaxel for use
in combination with pertuzumab and trastuzumab for the
treatment of HER2-positive metastatic breast cancer [27].
Results showed that this combination was highly active
and well tolerated, with a low incidence of AEs [27].
Additionally, preliminary safety results from the ongoing
phase IIIb PERUSE study (NCT01572038) have shown that
both paclitaxel and nab-paclitaxel appear to be feasible and
tolerable chemotherapy partners for trastuzumab and
pertuzumab for first-line HER2-positive advanced breast
cancer, with no unexpected safety signals observed [28].
Conclusions
In summary, the combination of pertuzumab, trastuzumab,
and vinorelbine, given as separate infusions, appears to be
Perez et al. Breast Cancer Research  (2016) 18:126 Page 12 of 13active and reasonably well tolerated for first-line treatment
of HER2-positive locally advanced or metastatic breast
cancer, and offers a viable alternative to the standard of care
(pertuzumab, trastuzumab, and docetaxel) for patients who
cannot receive docetaxel.
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